Disease modifying treatments (DMTs): starting guidelines
Evidence-based neurology checklist on disease modifying treatments (dmts): starting guidelines: Indications for starting DMTs At least 1 clinical event with ≥2 typical brain lesions There is no need for an escalation approach Consider the risk versus efficacy in individual cases Benefits of…
Indications for starting DMTs
- At least 1 clinical event with ≥2 typical brain lesions
- There is no need for an escalation approach
- Consider the risk versus efficacy in individual cases
Benefits of starting DMTs early
Conditions guiding choice of DMT
Precautions before starting DMTs
References
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777-788.
- Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14:17562864211039648.
- Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 2018; 25:1262-e110.
- Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 2017; 23:1233-1240.
